Rosemont Pharmaceuticals, Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Rosemont Pharmaceuticals, Ltd.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
Rosemont Celebrates One Year Of Independence With 49% Growth
A year on from being spun-out of Perrigo and acquired by private equity, liquid generics specialist Rosemont Pharmaceuticals has revealed new details of the UK-based firm’s operations.
Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
Perrigo Moves Closer To Exclusive Consumer Focus With UK Rx Generics Business Sale
Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.